- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells ; volume:1 ; number:1 ; day:7 ; month:11 ; year:2013 ; pages:1 ; date:11.2013
Journal for ImmunoTherapy of Cancer ; 1, Heft 1 (7.11.2013), 1, 11.2013
- Creator
-
Lu, Hailing
- Contributor
-
Yang, Yi
Groh, Veronika
Spies, Thomas
Dietsch, Gregory
Matthews, Maura
Disis, Mary L.
Hershberg, Robert
SpringerLink (Online service)
- DOI
-
10.1186/2051-1426-1-S1-P44
- URN
-
urn:nbn:de:1111-2016072650420
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lu, Hailing
- Yang, Yi
- Groh, Veronika
- Spies, Thomas
- Dietsch, Gregory
- Matthews, Maura
- Disis, Mary L.
- Hershberg, Robert
- SpringerLink (Online service)
Other Objects (12)
Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression
Chronic NKG2D engagement in vivo differentially impacts NK cell responsiveness by activating NK receptors
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Circulating CD56+ NKG2D+ NK cells and postoperative fertility in ovarian endometrioma
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Der NK-Zellrezeptor NKG2D als Zielstruktur für eine Antikörper-basierte therapeutische Immunmodulation
Fc-optimierte NKG2D-Fusionsproteine zur Induktion von NK-Zell Reaktivität gegen Leukämien
P24. Aviscumine enhances NK- cytotoxicity against tumor cells
Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients
2337
Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression
Chronic NKG2D engagement in vivo differentially impacts NK cell responsiveness by activating NK receptors
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Circulating CD56+ NKG2D+ NK cells and postoperative fertility in ovarian endometrioma
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Der NK-Zellrezeptor NKG2D als Zielstruktur für eine Antikörper-basierte therapeutische Immunmodulation
Fc-optimierte NKG2D-Fusionsproteine zur Induktion von NK-Zell Reaktivität gegen Leukämien
P24. Aviscumine enhances NK- cytotoxicity against tumor cells
Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients
2337
Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression
Chronic NKG2D engagement in vivo differentially impacts NK cell responsiveness by activating NK receptors
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
Circulating CD56+ NKG2D+ NK cells and postoperative fertility in ovarian endometrioma
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
Der NK-Zellrezeptor NKG2D als Zielstruktur für eine Antikörper-basierte therapeutische Immunmodulation
Fc-optimierte NKG2D-Fusionsproteine zur Induktion von NK-Zell Reaktivität gegen Leukämien
P24. Aviscumine enhances NK- cytotoxicity against tumor cells
Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson’s disease patients
2337
Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer